Lidocaine/Lidocaine Hydrochloride/Lidomar/Professional DNA Collection Kit/Xylocaine Viscous Periodontal Sol: 2% Lidocaine/Lidocaine Hydrochloride/Lidomar/Professional DNA Collection Kit/Xylocaine Viscous Oropharyngeal Sol: 2% Lidocaine/Lidocaine Hydrochloride/Lidocaine Hydrochloride, Dextrose/Lidocaine, Dextrose/Xylocaine/Xylocaine MPF Intravenous Inj Sol: 0.5%, 1%, 2%, 0.4-5%, 0.8-5% Lidocaine/Lidocaine Hydrochloride Intravenous Sol: 1% This is particularly important in children because of their frequency of eating.ħT Lido/ALOCANE/Astero/DermacinRx Lidogel/DermacinRx Lidorex/LidoRx/SUN BURNT PLUS/Tranzarel Topical Gel: 2%, 2.8%, 3%, 4%ħT Lido/Anestacon/Glydo/Lidocaine/Lidocaine Hydrochloride/Xylocaine/Xylocaine Topical Jelly Topical Jelly: 2%ĪLOCANE/Aspercreme with Lidocaine/Lidocaine/Lidocaine Hydrochloride Topical Spray: 4%ĪLOCANE/LidoDose/LidoDose Pediatric Topical Swab: 3%, 4%ĪNASTIA/GEN7T/Lidocaine/Lidocaine Hydrochloride/LIDO-K/LIDO-SORB/LIDOZION/Numbonex/Senatec/Zionodi Topical Lotion: 2.75%, 3%, 3.5%ĪneCream/Aspercreme with Lidocaine/BenGay/Blue Tube/CidalEaze/Gold Bond/LidaMantle/Lidocaine/Lidocaine Hydrochloride/LidoHeal-90/Lidosense 4/Lidotral/LMX 4/LMX 4 with Tegaderm/LMX 5/Lydexa/RectaSmoothe/RectiCare Topical Cream: 3%, 3.88%, 4%, 4.12%, 5%Īspercreme with Lidocaine/Blue-Emu/GEN7T/Lidocaine/Lidocare/Lidofore/LidoReal-30/Salonpas Lidocaine Topical Film: 3.5%, 4%Īspercreme with Lidocaine/Blue-Emu/GEN7T/Lidocaine/Lidocare/Lidofore/Lidozo/Salonpas Lidocaine Transdermal Film: 3.5%, 4%Īspercreme with Lidocaine/Lidocaine/Lidocaine Hydrochloride/VacuStim Silver/Xylocaine/Xylocaine Topical Solution/Zilactin-L Topical Sol: 1mL, 4%, 40mgĭERMALID/Lidocaine/Lidoderm/ZTlido Transdermal Film ER: 1.8%, 5% For this reason, food should not be ingested for 60 minutes following use of local anesthetic preparations in the mouth or throat area. When topical anesthetics are used in the mouth, the topical anesthesia may impair swallowing and thus enhance the danger of aspiration. To ensure safety, doses should be measured by an accurate device, administered no more often than every 3 hours, used only for the prescribed indication, and stored safely out of the reach of children immediately after use. For other conditions, the use of viscous lidocaine in neonates, infants, and children 3 years of age and younger should be limited to those situations where safer alternatives are not available or have failed. Advise parents and caregivers with teething pain concerns to follow the American Academy of Pediatrics recommendations for the management of teething pain, which include using a teething ring chilled in the refrigerator (not frozen) and gently rubbing or massaging the gums with a finger. The FDA recommends against the use of topical pain relievers for teething pain due to the fact that they wash out of the mouth within minutes of application and can cause serious adverse reactions if they are swallowed in excessive amounts. Of the 22 cases, 6 cases resulted in death, 3 were categorized as life-threatening, 11 required hospitalization, and 2 required medical intervention without hospitalization. The FDA reviewed 22 cases of serious adverse events that occurred in infants and young children between 5 months and 3.5 years of age after receiving lidocaine viscous solution for the treatment of mouth pain due to teething or stomatitis or who had accidental ingestions. Do not use lidocaine viscous solution for the treatment of teething pain in infants and young children due to the risk of serious adverse reactions, including seizures, cardiopulmonary arrest, severe brain injury, and death. Non-prescription (OTC) products should not be used without healthcare professional advice in those under 2 years of age, or as directed on the product label. Certain products, such as lidocaine transdermal patches, have not been FDA-approved for application to pediatric patients. Similar increases in systemic exposure are possible with repeat topical application. Repeated doses of parenteral lidocaine may cause a significant increase in blood concentrations with each successive dose these increases may be poorly tolerated by pediatric patients, particularly by those who are debilitated or the acutely ill. Resuscitative equipment and facilities should be readily available in case of an emergency when using parenteral products. When multiple formulations of lidocaine are used at once, the amount systemically absorbed from all formulations must be considered. Lidocaine dosages in pediatric patients should be reduced, commensurate with age, body weight and physical condition. Children, infants, neonates, teething pain
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |